IMR Press / FBE / Volume 4 / Issue 7 / DOI: 10.2741/E549

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Autoimmunity and lung transplantation

Show Less
1 Department of Surgery and Cardiothoracic Surgery, Washington University School of Medicine, Campus Box 8109, 660 S. Euclid Avenue, St. Louis, MO 63110
2 Department of Pathology and Immunology, Washington University School of Medicine, Box 8109-3328 CSRB, 660 S. Euclid Avenue, St. Louis, MO 63110

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2012, 4(7), 2378–2388;
Published: 1 June 2012

Lung transplantation is a viable treatment option for a variety of end-stage lung diseases. Since the first successful human lung transplant about 20 years ago, tremendous progress has been made in this field. However, lung allografts have the poorest long term survival compared to other solid organs. The predominant reason for this is the development of chronic rejection, also known as bronchiolitis obliterans syndrome (BOS). Although the traditional view supports alloimmunity as the major cause of chronic rejection, emerging evidence reveals a complex interplay of multiple etiologies including perioperative stressors, inflammation, and autoimmunity along with alloimmunity. Identification of autoimmunity in the pathogenesis of BOS is an exciting recent finding in lung transplantation and promises to introduce novel strategies for future therapeutic interventions. In this review, we discuss recent studies and concepts related to the role of autoimmunity in the development of BOS.

Bronchiolitis Obliterans syndrome
Primary graft dysfunction
Lung yransplant
Back to top